An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date

References

• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
   PubMed Web of Science ®Google Scholar
• Hassinger TE, Sawyer RG. Should We Immediately Start Antibiotics in Every Patient with a Clinical Suspicion of HAP/VAP? Semin Respir Crit Care Med. 2017;38(3):245–252.
   PubMed Web of Science ®Google Scholar
• Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28(2):108–121.
   PubMed Web of Science ®Google Scholar
• Metersky ML, Wang Y, Klompas M, et al. Trend in ventilator-associated pneumonia rates between 2005 and 2013. J Am Med Assoc. 2016;316(22):2427–2429.
   PubMed Web of Science ®Google Scholar
• Burgos J, Falcó V, Almirante B. Chemical pharmacotherapy for hospital-acquired pneumonia in the elderly. Expert Opin Pharmacother. 2019;20(4):423–434.
   PubMed Web of Science ®Google Scholar
• Bouadma L, Sonneville R, Garrouste-Orgeas M, et al. Ventilator-Associated Events: prevalence, Outcome, and Relationship with Ventilator-Associated Pneumonia. Crit Care Med. 2015;43(9):1798–1806.
   PubMed Web of Science ®Google Scholar
• Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries. Am J Infect Control. 2008;36(4SUPPL):S101–S108.
   PubMedGoogle Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbial etiologies of Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51((SUPPL):1.
   PubMedGoogle Scholar
• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288–1301.
   PubMed Web of Science ®Google Scholar
• Gupta N, Limbago BM, Patel JB, et al. Carbapenem-resistant enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60–67.
   PubMed Web of Science ®Google Scholar
• Dantas RC, Ferreira ML, Gontijo-Filho PP, et al. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol. 2014;63(12):1679–1687.
   PubMedGoogle Scholar
• Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014;27(6):573–577.
   PubMedGoogle Scholar
• Poirel L, Aurélie J, Nordmann P. Polymyxins: antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes Laurent Poirela,b,c, Aurélie Jayola,b,c and Patrice Nordmann. Clin Microbiol Rev. 2017;30(2):557–596.
   PubMed Web of Science ®Google Scholar
• FDA. Recarbrio Label FDA. 2019;1–17.
   Google Scholar
• Torres A, Rank D, Melnick D, et al. Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA-specified end points. Open Forum Infect Dis. 2019;6:4.
   Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in <span class= “named-content genus-species” id=“named-content-1”>Enterobacteriaceae</span> . Antimicrob Agents Chemother. 2017;61(11):e01443–17.
   PubMed Web of Science ®Google Scholar
• Wunderink R, Giamarellos-Bourboulis E,  Rahav G, et al. Meropenem/vaborbactam (Vabomere) vs best available therapy for CRE Infections: TANGO II randomized, controlled phase 3 study results. Presented at: IDWeek; 2017; San Diego (CA). 2017; 2017.
   Google Scholar
• Noval M, Banoub M, Claeys KC, et al. The Battle Is on: new Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Curr Infect Dis Rep. 2020;22(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sabet M, Tarazi Z, Griffith DC. Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model. Antimicrob Agents Chemother. 2018 Oct;63(1):1–5.
   Web of Science ®Google Scholar
• Dobias J, Dénervaud-Tendon V, Poirel L, et al. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36(12):2319–2327.
   PubMed Web of Science ®Google Scholar
• Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens - Full Text View - ClinicalTrials.gov [Internet]. [ cited 2021 Mar 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03032380
   Google Scholar
• Wunderink RG, Wunderink RG, Matsunaga Y, et al. LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study. Open Forum Infect Dis. 2019 Oct 6;6(Supplement_2):S994–S994.
   Google Scholar
• Los-Arcos I, Burgos J, Falcó V, et al. An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia. Expert Opin Pharmacother. 2020;21(9):1005–1013.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Ü K, et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299–1311.
   PubMed Web of Science ®Google Scholar
• Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019;38(10):1787–1794.
   PubMed Web of Science ®Google Scholar
• Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113–2118.
   PubMed Web of Science ®Google Scholar
• Kropp H, Gerckens L, Sundelof JG, et al. Antibacterial activity of imipenem: the first thienamycin antibiotic. August Rev Infect Dis. 1985;7Suppl 3:S389–S410.
   PubMedGoogle Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative Review of the Carbapenems. Drugs. 2007;67(7):1027–1052.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam is a potent inhibitor of the kpc-2 -lactamase and restores imipenem susceptibility in kpc-producing enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(6):1–9.
   Web of Science ®Google Scholar
• Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorganic Med Chem Lett. 2014;24(3):780–785.
   PubMed Web of Science ®Google Scholar
• Rodloff AC, Goldstein EJC, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother. 2006;58(5):916–929.
   PubMed Web of Science ®Google Scholar
• Smith JR, Rybak JM, Claeys KC. Imipenem-Cilastatin-Relebactam: a Novel β-Lactam–β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Pharmacotherapy. 2020;40(4):343–356.
   PubMed Web of Science ®Google Scholar
• Shlaes DM. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013;1277(1):105–114.
   PubMedGoogle Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014;78(4):443–448.
   PubMed Web of Science ®Google Scholar
• El-Gamal MI, Brahim I, Hisham N, et al. Recent updates of carbapenem antibiotics. Eur J Med Chem. 2017;131:185–195.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem–Relebactam and Meropenem–Vaborbactam: two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018;78(1):65–98.
   PubMed Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):1–8.
   Web of Science ®Google Scholar
• Canver MC, Satlin MJ, Westblade LF, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019 Jul;63(9):1–5.
   Web of Science ®Google Scholar
• Galani I, Souli M, Nafplioti K, et al. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016. Eur J Clin Microbiol Infect Dis. 2019;38(6):1143–1150.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.
   PubMed Web of Science ®Google Scholar
• Schmidt-Malan SM, Mishra AJ, Mushtaq A, et al. In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli. Antimicrob Agents Chemother. 2018 May;62(8):1–8.
   Web of Science ®Google Scholar
• Campanella TA, Gallagher JC. A clinical review and critical evaluation of imipenem-relebactam: evidence to date. Infect Drug Resist. 2020;13:4297–4308.
   PubMed Web of Science ®Google Scholar
• Asempa TE, Nicolau DP, Kuti JL. In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(9):1–9.
   Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–5031.
   PubMed Web of Science ®Google Scholar
• Lob SH, Karlowsky JA, Young K, et al. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017. J Med Microbiol. 2020 Feb;69(2):207–217.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA. In vitro evaluation of the activity of imipenem-relebactam against 451 recent clinical isolates of Bacteroides group and related species. Antimicrob Agents Chemother. 2016;60(10):6393–6397.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Tyrrell KL, et al. Comparative in vitro activities of relebactam, imipenem, the combination of the two, and six comparator antimicrobial agents against 432 strains of anaerobic organisms, including imipenem-resistant strains. Antimicrob Agents Chemother. 2018;62(2):1–8.
   Web of Science ®Google Scholar
• Bhagunde P, Patel P, Lala M, et al. Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):748–758.
   PubMedGoogle Scholar
• Rizk ML, Rhee EG, Jumes PA, et al. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. Antimicrob Agents Chemother. 2018 Jan;62(3):1–11.
   Web of Science ®Google Scholar
• Karaiskos I, Galani I, Souli M, et al. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15(2):133–149.
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Grāmatniece A, et al. New β-Lactam–β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 Nov;34(1):1–61.
   Google Scholar
• Motsch J, Cum DO, Stus V, et al., RESTORE-IMI 1: a Multicenter, Randomized, Doubleblind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients with Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 70(9): 1799–1808. 2020.
   PubMed Web of Science ®Google Scholar
• Titov I, Wunderink RG, Roquilly A, et al. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2020 Aug:ciaa803. DOI: https://doi.org/10.1093/cid/ciaa803.
   Web of Science ®Google Scholar
• Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014;69(8):2043–2055.
   PubMed Web of Science ®Google Scholar
• Rhee EG, Rizk ML, Calder N, et al. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants. Antimicrob Agents Chemother. 2018 Jun;62(9):1–16.
   Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. in Subjects with Complicated Intra-abdominal Infection. Antimicrob Agents Chemother. 2016;60(10):6234–6243.
   PubMed Web of Science ®Google Scholar
• Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72(9):2616–2626.
   PubMed Web of Science ®Google Scholar
• FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia | FDA [Internet] [ cited 2021 Mar 15]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-antibiotic-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated
   Google Scholar
• Recarbrio | European Medicines Agency [Internet]. [ cited] 2021 Mar 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/recarbrio
   Google Scholar